Global Liposome Development Service Market Growth (Status and Outlook) 2023-2029

Global Liposome Development Service Market Growth (Status and Outlook) 2023-2029

Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.

LPI (LP Information)' newest research report, the “Liposome Development Service Industry Forecast” looks at past sales and reviews total world Liposome Development Service sales in 2022, providing a comprehensive analysis by region and market sector of projected Liposome Development Service sales for 2023 through 2029. With Liposome Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome Development Service industry.

This Insight Report provides a comprehensive analysis of the global Liposome Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposome Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liposome Development Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome Development Service and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome Development Service.

The global Liposome Development Service market size is projected to grow from US$ 997.8 million in 2022 to US$ 1750.5 million in 2029; it is expected to grow at a CAGR of 8.4% from 2023 to 2029.

Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of Liposome Development Service market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Liposomes
Lipid Nanoparticles

Segmentation by application
Preclinical
Clinical
Commercial

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles

Please note: The report will take approximately 2 business days to prepare and deliver.